跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 59 条关于
“parainfluenza”
全部
59
临床试验
33
药物
10
机构
0
资讯
16
去年
Vicebio Secures $100 Million to Advance RSV and hMPV Combination Vaccine
2年前
RSV Vaccine Development Surges with New Approvals and Diverse Strategies
去年
Blue Lake and CyanVac Report Promising Phase 1 Results for Intranasal COVID-19 Vaccine CVXGA
3年前
Blue Lake Biotechnology's Nasal COVID-19 Vaccine Shows 86% Efficacy in Phase 1 Trial
11个月前
Clover Biopharmaceuticals Reports Positive Phase I Data for First-in-Class RSV-hMPV-PIV3 Combination Vaccines
去年
Blue Lake and CyanVac Present Promising Intranasal Vaccine Data at ISV Annual Congress
去年
Blue Lake and CyanVac's Intranasal COVID-19 Vaccine Shows Promise in Phase 2a Trial
去年
CyanVac's Intranasal COVID-19 Vaccine Candidate, CVXGA, Enters Phase 2b Trial
去年
Blue Lake Biotech's Intranasal RSV Vaccine Shows Promise in Pediatric Trial
3年前
Clover Biopharmaceuticals Advances RSV Vaccine SCB-1019 with U.S. IND Clearance for Revaccination Study
第 1 页,共 2 页
上一页
下一页